Monroe Capital increased its credit facility to ProPharma Group to support the acquisitions of The Weinberg Group and Southwood Research. ProPharma is an existing portfolio company of Linden Capital Partners.

Based in Washington, D.C., The Weinberg Group is a FDA consultancy. For over 35 years, the company has provided pharmaceutical, biotechnology and medical device consulting services to companies of every size on every continent, supplying them with viable and efficient drug development pathways and compliance solutions.

Based in Buckinghamshire, UK, Southwood Research is a provider of pre-approval regulatory science services to the pharmaceutical and biotech industries.

ProPharma is an international, independent, single-source provider of comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and medical devices.

The additions of The Weinberg Group and Southwood Research will bolster ProPharma’s regulatory affairs capabilities, representing a truly unique end-to-end global regulatory practice.

MidCap Financial also participated in the transaction.

Monroe Capital is a private credit asset management firm specializing in direct lending and opportunistic private credit investing.